Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00958412
Recruitment Status : Terminated (Repros stopped the study for safety and FDA put the study on hold for safety.)
First Posted : August 13, 2009
Last Update Posted : June 24, 2014
Information provided by (Responsible Party):
Repros Therapeutics Inc.

Brief Summary:
This is an extension of the phase II, three-arm, parallel design, dose-ranging, placebo-controlled, randomized, double-blind, multicenter study in which placebo or one (1) of two (2) dose levels of Proellex® was administered once-daily for four (4) months.

Condition or disease Intervention/treatment Phase
Endometriosis Drug: Proellex® Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Premenopausal Women With Symptomatic Endometriosis-extension Study
Study Start Date : February 2009
Actual Primary Completion Date : August 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endometriosis

Arm Intervention/treatment
Experimental: Proellex®
25 mg Proellex®
Drug: Proellex®
one (1) 25 mg capsule daily
Other Name: CDB-4124

Primary Outcome Measures :
  1. To evaluate incidence of adverse events (AEs) and safety of Proellex® administered once daily [ Time Frame: two (2) separate treatment cycles of four (4) months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 48 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Only subjects treated in the ZPE-201 study will be allowed to enter the extension study.
  • Subjects who withdrew from ZPE-201 due to lack of treatment efficacy will also be invited to participate.

Exclusion Criteria:

  • All other subjects

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00958412

United States, Arizona
Advanced Clinical Therapeutics, LLC
Tucson, Arizona, United States, 85712
United States, California
Medical Center for Clinical Research
San Diego, California, United States, 92108
Compass Clinical Research
San Ramon, California, United States, 94583
United States, Florida
Comprehensive Clinical Trials
West Palm Beach, Florida, United States, 33409
United States, North Carolina
Physicians for Women
Cary, North Carolina, United States, 27518
United States, Ohio
HWC Women's Research Center
Miamisburg, Ohio, United States, 45322
United States, Texas
Clinical Trials of Texas/Institute for Women's Health
San Antonio, Texas, United States, 78229
Clinical Trials of Texas/Seven Oaks Women's Center
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Repros Therapeutics Inc.
Study Director: Andre van As, MD, PhD Repros Therapeutics Inc.

Responsible Party: Repros Therapeutics Inc. Identifier: NCT00958412     History of Changes
Other Study ID Numbers: ZPE-201 EXT
First Posted: August 13, 2009    Key Record Dates
Last Update Posted: June 24, 2014
Last Verified: June 2014

Keywords provided by Repros Therapeutics Inc.:
Pelvic pain
Oral progesterone blocker

Additional relevant MeSH terms:
Genital Diseases, Female